Methods and compositions for targeting secretory lysosomes
AssigneeBoehringer Ingelheim Phamaceuticals, Inc.
InventorsDaniel Rajotte, Alisa Kabcenell
Life of this patent
Estimating the term…
Abstract
This invention relates to methods and compositions for targeting proteins to secretory lysosomes. The invention further provides methods of use in drug screening assays, and methods of purifying secretory lysosomes.
Claims26
A secretory lysosome targeting fusion moiety comprising:
- (a) a polypeptide that specifically localizes to a secretory lysosome and (b) a label polypeptide.
A secretory lysosome targeting fusion moiety comprising:
- (a) a nucleotide sequence encoding a polypeptide that specifically localizes to a secretory lysosome and (b) a nucleotide sequence encoding a label polypeptide.
A cell line expressing a secretory lysosome targeting fusion moiety as deposited with the American Type Culture Collection and assigned accession number PTA-4571.
A method for detecting and quantifying degranulation comprising:
- (a) incubating a cell expressing a secretory lysosome targeting fusion moiety comprising a label molecule in the presence of a cell activator;
- (b) incubating the cell expressing the secretory lysosome targeting fusion moiety comprising a label molecule in the absence of the cell activator;
- and (c) detecting and quantifying the release of label in the supernatant in the presence of the cell activator compared to the release of label in the supernatant in the absence of the cell activator, wherein an increase in the release of label in the supernatant in the presence of the cell activator indicates degranulation.
A method for detecting and quantifying inhibition of degranulation comprising:
- (a) incubating a cell expressing a secretory lysosome targeting fusion moiety comprising a label molecule with a cell activator in the presence of a test substance;
- (b) incubating the cell expressing the secretory lysosome targeting fusion moiety comprising a label molecule with the cell activator in the absence of the test substance;
- and (c) detecting and quantifying a change in the release of label in the supernatant in the presence of the test substance compared to the release of label in the supernatant in the absence of test substance, wherein a decrease in the release of label in the supernatant in the presence of test substance indicates inhibition of degranulation.
A method for detecting and quantifying degranulation at the single cell level comprising:
- (a) incubating a cell expressing a secretory lysosome targeting fusion moiety comprising a label molecule in the absence of a cell activator;
- (b) detecting and quantifying the amount of label in the absence of a cell activator, (c) incubating the cell of step (a) in the presence of a cell activator;
- (d) detecting and quantifying the amount of label in the presence of the cell activator;
- and (e) detecting a change in the amount of label in the cell in the presence of the cell activator compared to the amount of label in the cell in the absence the cell activator, wherein a decrease in the amount of label indicates degranulation.
A method for detecting and quantifying degranulation at the single cell level comprising:
- (a) incubating a cell expressing a secretory lysosome targeting fusion moiety comprising a label molecule in the presence of a cell activator;
- (b) detecting and quantifying the amount of label in the presence of the cell activator, (c) incubating the cell of step (a) in the presence of the cell activator and a test substance;
- (d) detecting and quantifying the amount of label in the presence of the cell activator and the test substance;
- and (e) comparing the amount of label in the cell in the presence of the test substance to the amount of label in the cell in the absence the test substance, wherein an increase in the amount of label in the presence of the test compound indicates degranulation.
Dependencies are inferred from the claim text.